Investigation of the spectrum of physiological activities of the heptapeptide Semax, an ACTH(4-10) analogue
Levitskaya NG, Glazova NYu, Sebentsova EA, Manchenko DM, Vilensky DA, Andreeva LA, Kamensky AA, Myasoedov NF
Neurochemical Journal (2008)
The Ashmarin / Moscow State University group's decade-on synthesis of the Semax research program — the thesis that the Pro-Gly-Pro stabilization separated melanocortin neurotropic activity from hormonal activity, enabling chronic dosing without engaging the systemic stress axis.
This 2008 review from the Levitskaya / Glazova / Sebentsova / Manchenko / Andreeva / Kamensky / Myasoedov group at Moscow State University (Faculty of Biology) and the Institute of Molecular Genetics is the decade-on synthesis of the Semax research program. The thesis: Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic heptapeptide analogue of ACTH(4-10) with a stabilizing Pro-Gly-Pro C-terminal extension, has lost the hormonal activity (corticotropic, melanotropic) of native melanocortins while retaining their neurotropic activity. This separation is what makes chronic CNS dosing feasible without engaging the systemic stress axis.
Within the neurotropic envelope, the review consolidates a decade of inventor-group evidence that Semax exhibits a broad spectrum of activities: nootropic (learning and memory facilitation), neuroprotective (against ischemic, hypoxic, and neurotoxic insults), anxiolytic, antidepressant, analgesic, and developmental effects when administered in the neonatal window. The authors argue the pleiotropy is mechanistically coherent rather than a list of coincidences — Semax modulates melanocortin and monoaminergic systems and upregulates BDNF (brain-derived neurotrophic factor) and TrkB receptor expression in hippocampus and basal forebrain. The conclusion frames Semax as a regulatory peptide whose effects vary by dose and route, supporting the Russian-registered nasal-drop formulation indicated for ischemic stroke and cognitive disorders.
This is the bibliographic anchor for any English-language reader trying to understand why the Ashmarin group's claims for Semax span nootropic, neuroprotective, anxiolytic, and analgesic domains — claims that look incoherent in isolation but that the review threads together through the melanocortin + BDNF + monoaminergic substrate.
The full body text of the 2008 review was not accessible to the agent-pipeline extraction pass; the structured extraction below is reconstructed from (a) the published English-translation abstract in Neurochemical Journal, (b) verbatim citations of this paper in subsequent peer-reviewed work from the same group (especially the Manchenko et al. 2010 routes-of-administration paper and the Koroleva-Myasoedov 2018 synthesis), and (c) the Russian-language meta-citation in the Dodonova melanocortin review on CyberLeninka. The extraction is explicit about which claims trace to which sources; numbers (sample sizes, percentages, p-values) are not asserted unless directly verifiable from accessible sources.
Three structural caveats apply to the underlying program this review summarizes:
-
Inventor-group institutional positioning. This is the Moscow State University / Institute of Molecular Genetics laboratory that synthesized Semax. The review is by the developers, with the expected program-promotional framing. The breadth-of-spectrum claim is presented as evidence of mechanistic coherence rather than as a marketing-style "universal drug" claim, but the routine institutional conflict-of-interest applies.
-
Single-laboratory dominance of the underlying literature. Most behavioral and mechanistic readouts come from the Ashmarin / Kamensky / Levitskaya group itself or close collaborators. Independent Western replication of the rodent-program findings in healthy adult subjects is thin. The Russian clinical literature (stroke, cognitive disorders) exists and is real, but the recreational-use ("nootropic in healthy adults") evidence base rests substantially on this group's work.
-
Biphasic dose-response, route-dependent effect spectrum. The review itself acknowledges that the "right" dose is task-dependent and not transferable across endpoints — nootropic, analgesic, and anxiolytic effects engage partly different brain structures and emerge at different doses and routes. This complicates protocol-level recommendations even when the molecule's overall mechanistic story is accepted.
The unresolved mechanistic question the review itself flags: the melanocortin-receptor subtype mediating Semax's effects was not conclusively assigned in 2008. MC4R is implicated but binding studies did not show classical melanocortin-receptor affinity, suggesting either a non-classical melanocortin site or an indirect mechanism via BDNF upregulation. This remains an active question in subsequent work.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.